Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Transcatheter Chemoembolization Market $21.2 Billion by 2027

The global market for transcatheter chemoembolization (TACE) to reach $21.2 billion by 2027, growing at 5.0% CAGR over the forecast period, driven by increased adoption of minimally invasive surgeries, technological innovations and rising number of cancer cases.

Global Transcatheter Chemoembolization Market

Hepatocellular carcinomas (HCC) and renal cell carcinomas are one of the commonest malignancies world-wide, largely due to the high prevalence of hepatitis B infection in the developing world.

  • Transcatheter arterial chemoembolization (TACE) or transarterial chemoembolization (TAE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor’s blood supply.
    • Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor.
      • These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways. TACE is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth.
Hepatocellular-Carcinoma-Clinical-Trials-Devices

The global market for transcatheter arterial chemoembolization provides market size (revenue $million, 2017 to 2027) and number of procedures for TACE, market size (revenue $million, 2017 to 2027) and volume (number of units) for micro catheter, micro guidewire used in TACE procedures, market share analysis by key players, growth trends and forecast (CAGR%, 2021 to 2027).

The global transcatheter arterial chemoembolization market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, South Korea, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America region accounted for a major share of the market, due to gradually increasing cases of HCC, increasing investment, novel drug delivery systems development and presence of major market players in the region.
    • Most of the major players operating in the region have made a series of strategic acquisitions leading to the increase in their market share.
      • Increasing cancer prevalence in the region is the one of the key factors contributing to the growth of transcatheter arterial chemoembolization market.
  • The TACE market has been estimated based on HCC prevalence and incidence in each country or region using the Barcelona Clinic Liver cancer (BCLC) staging system and treatment strategy and Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma, proposed by the Japan Society of Hepatology (JSH), 2012.

The global market for transcatheter arterial chemoembolization research report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered.

Major competitors operating in the global transcatheter chemoembolization market and included in this report are Abbott Laboratories, Inc., ABK Biomedical, Inc., Asahi Intecc Co., Ltd., BioSphere Medical, Inc., (Merit Medical Systems, Inc.), Blockade Medical,  (BALT International), Boston Scientific Corporation, Braile Biomedica, BTG International, Cook Medical, Inc., Depuy Synthes (JnJ), Guerbet Group, Magle Life Science, Medtronic plc (Covidien plc), Penumbra, Inc., Pfizer, Inc., PharmaCept, Piolax Medical Devices, Inc. (Piolax, Inc.), Sirtex Medical Limited, Stryker Corporation, Surefire Medical, Inc., Terumo Medical Corporation (Sequent Medical), and Vascular Solutions, Inc.

  • TACE Market 
    • Market size by Geography
    • Number of Procedures by Geography
  • Product
    • Micro Catheter
      • Market size by Geography
      • Number of Units Sold by Geography
    • Micro Guidewire
      • Market size by Geography
      • Number of Units Sold by Geography
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, South Korea, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  • Company Profiles
    • Abbott Laboratories, Inc.
    • ABK Biomedical, Inc.
    • Asahi Intecc Co., Ltd.
    • BioSphere Medical, Inc. (Merit Medical Systems, Inc.)
    • Blockade Medical, USA (BALT International)
    • Boston Scientific Corporation
    • Braile Biomedica
    • BTG International
    • Cook Medical, Inc.
    • Depuy Synthes (Johnson & Johnson)
    • Guerbet Group
    • Magle Life Science
    • Medtronic plc (Covidien plc)
    • Penumbra, Inc.
    • Pfizer, Inc.
    • PharmaCept
    • Piolax Medical Devices, Inc. (Piolax, Inc.)
    • Sirtex Medical Limited
    • Stryker Corporation
    • Surefire Medical, Inc.
    • Terumo Medical Corporation (Sequent Medical)
    • Vascular Solutions, Inc.

To request Table of Contents and Sample Pages of this report visit, contact us:
https://www.ihealthcareanalyst.com/global-transcatheter-arterial-chemoembolization-tace-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]